IL7R (Interleukin 7 Receptor)

Its spatial association with immune markers such as CD127 and CD86 further supports its regulatory role. These findings provide mechanistic insights and highlight CCL5 as a promising biomarker and immunotherapeutic target in osteosarcoma.

P2, N=171, Completed, Incyte Corporation | Active, not recruiting --> Completed

In comparison to PD1 blockade, combined treatment (IT plus PD1 blockade) significantly increased the number of intermediate IRs-expressing CD8+TILs, while reducing the number of high IRs-expressing CD8+TILs. These results indicated that combined treatment enhanced the function and decelerated the increase in IRs expression of CD8+TILs, deferring the developmental process of CD8+TILs exhaustion.

ICI-IA has the potential to teach us about mechanisms underlying the biology and evolution of other forms of inflammatory arthritis. In this review, we summarize our current understanding of ICI-IA and propose promising avenues for future research.

However, conventional ex vivo expansion protocols using zoledronic acid (Zol) and IL-2 often lead to terminal differentiation and diminished effector function. In orthotopic tumor models, γδ2 T-Da cells enhanced tumor control, reduced TNBC metastasis, and prolonged survival of GBM-bearing mice. These results suggest that dasatinib improves γδ T cell yield and function, providing a practical and translatable strategy for optimizing γδ T cell-based adoptive therapy, particularly for solid tumors.Trial registration: Trial number: CMUH111-REC3-185.

P1, N=16, Recruiting, Chulalongkorn University | Not yet recruiting --> Recruiting | Initiation date: Sep 2025 --> Jan 2026

P1, N=9, Recruiting, Chulalongkorn University | Trial primary completion date: Dec 2026 --> Dec 2027 | Trial completion date: Dec 2027 --> Dec 2028

This is reflected in the raft of mutants and variants of IL-7R components and downstream signaling molecules that have been identified in the context of immunodeficiencies, autoimmune disorders and lymphoid malignancies, but also through the use of pathway modulators as therapeutics. This review provides an overview of IL-7R biology, the role of mutations and variants affecting IL-7R signaling pathway components in the etiology of immune cell diseases and the specific therapies related to this pathway.

Our findings elucidate mechanisms of cell death-associated genes in CD4+ T cell subgroups, with experimentally grounded biomarkers offering therapeutic options for HGSOC.

P1, N=10, Completed, Zhejiang University | Recruiting --> Completed | N=16 --> 10 | Trial completion date: Aug 2025 --> May 2025 | Trial primary completion date: Aug 2025 --> May 2025

NDMA likely promotes BLCA through multi-target and multi-pathway mechanisms. The identified core genes serve as potential diagnostic biomarkers, and the proposed AOP provides a theoretical basis for environmental risk assessment and targeted intervention strategies.

We also identify a human ILC1 subset as Lin-CD127+CD161-CRTH2-CD117- (CD161- ILC1s) that can be generated from umbilical cord blood CD34+ hematopoietic stem cells. This method could provide a reliable source of ILC1s for potential adoptive transfer therapies in AML, offering a therapeutic approach to prolong disease-free survival in AML.